Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing registry study of nifekalant hydrochloride for injection
CTR20191724Phase 4Suspended
- Sponsor
- Biokin Pharmaceutical
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of nifekalant in ventricular tachycardia (VT), ventricular fibrillation (VF), sponsored by Biokin Pharmaceutical. Started Mar 2017; status: suspended.
02
Drugs
nifekalant
03
Conditions
ventricular tachycardia (VT)ventricular fibrillation (VF)
Beyond the preview
Go deeper on CTR20191724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191724.